Back to search
Neuromuscular Agents
Clinical trial pipeline · Data from ClinicalTrials.gov
See which Neuromuscular Agents trials you may qualify forClinical trial pipeline · Data from ClinicalTrials.gov
See which Neuromuscular Agents trials you may qualify forPhase 1/2, open-label study of ETX-636 in participants with advanced solid tumors
ANDROMEDA is a first-in-human, Phase I/II, open-label, multicenter study of AZD9750 in participants with metastatic prostate cancer. The trial evaluates safety,…
The study is a Phase 1b/2, multi-center, open-label, dose escalation trial evaluating the safety and preliminary efficacy of sapanisertib and serabelisib (PIKTO…
Study STX-478-101 (LY4064809) is a multipart, open-label, phase 1/2 study evaluating the safety, tolerability, pharmacokinetics (PK), and preliminary antitumor…
The purpose of this study is to assess the safety and efficacy of NT 201 compared with placebo in participants with moderate to severe platysma prominence. The…
A quantitative neuromuscular monitoring device is desirable to titrate the depth of neuromuscular block (NMB) during a procedure, and to prevent residual effect…
The effect of muscle relaxants need to be followed during surgery and before waking up the patient, the anesthesiologist has to make sure that the effect of mus…
This is an active-comparator controlled study to evaluate the effect of sugammadex compared to neostigmine/glycopyrrolate for reversal of rocuronium on the inci…
In this study, the antagonism of neostigmine, a cholinesterase inhibitor, on continuous infusion of mivacurium during foot and ankle surgery under general anest…